topeesp.gif (5672 bytes)

[ Index ]

EPI-PCVC Mailing List

Messages

Go to #: 94
Go to #: 93
Go to #: 92

#92 De:  Enrique Lopez <m940916@prodigy.net.mx>
Enviado: Miércoles, 15 de Marzo de 2000 04:54
Asunto: Papel de la glibenclamida sobre la enf ateroesclerosa/Role of glybenchlamida on atherosclerotic disease
Sponsored by: Laboratorios Bago
Saludos estimados colegas:
Un abrazo a todos, desearia conocer su opinion sobre dos puntos:
1) Acerca del papel que juegan las sulfonilureas especialmente el de la glibenclamida, sobre la aterogenesis y eventos cardiovasculares, en los pacientes diabeticos tipo 2. y
2) Se le podria considerar a la glibenclamida un factor que potencilice a la enfermedad ateroescleritica entre los pacientesdiabeticos tipo 2?.
atte.
Nota del Moderador reemplazante: envio la consulta del Dr. Lopez al Foro de Farmacologia y Terapeutica para conocer tambien la
opinion de los colegas

Hello, dear colleagues:
Hugs for everyone; I would like to learn your opinion about two items:
1) Concerning the role that sulfonylurea compounds play, especially that of glybenchlamidia on atherogenesis and cardiovascular events in diabetic patients type 2, and
2) Could glybenchlamidia be considered a factor that fosters atherosclerotic disease among diabetic patients type 2? Sincerely,
Enrique Lopez
Note from the substitute Moderator: I send Dr. Lopez' consult to the Forum on Pharmacology and Therapeutics to learn the opinion of
the colleagues as well.

Top

#93 De: Jorge Did Nuñez <jdid@infomed.sld.cu>
Enviado: Miercoles, 15 Mar 2000 22:42:30
Asunto: Estratificacion de Riesgo/Risk Stratificatio
Sponsored by: Deutsche Bank
Estimados colegas:
Qusiera aprovechar la publicacion en el congreso del documento del Profesor John Chalmers titulado "The 1999 WHO-ISH hypertension guidelines stratifiying the risk to treat the patient", basado en los postulados de las "1999 World Health
Organization- International Society of Hypertension Guidelines for the Management of Hypertension", para formular tres interrogantes que me
surgieron luego de estudiar deternidamente el documento de referencia.
a). En el grupo de BAJO RIESGO, dado que el riesgo se cuantifica en menos del 15%, ¿que valores corresponden a la ¨hipertertension borderline¨ de a cuerdo a la expresion ¨riesgo particularmente bajo? (pagina 162).
b). En los grupos de MEDIANO RIESGO y ALTO RIESGO, cuyos rangos terminan y comienzan en un valor de 20%, como se puede eliminar el solapamiento entre los grupos (paginas 162-53).
c). ¿Puede ser usada la metodologia de Estratificacion de Riesgo para la Cuantificacion Pronostica presentada en la Tabla 3 para todos los pacientes con hipertension arterial, o esta es solamente aplicable a los pacientes entre los frangos de edad seguidos en  el   estudio Framingham, de acuerdo a lo expresado en la parte final del primer parrafo del titulo Stratification of patients with hypertension by absolute level of cardiovascular risk?
Cordialmente

Dear colleagues:
I would like to take advantage of the publication in the congress of Professor John Chalmers' document titled "The 1999 WHO-ISH hypertension guidelines stratifying the risk to treat the patient", based on the postulates from the "1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension", to ask three questions that occurred to me after studying in detail the mentioned document.
a) In the LOW RISK group, since the risk is quantified in less than a 15%, what values correspond to "borderline hypertension"
according to the expression "particularly low risk"? (Page 162).
b) In the MEDIUM and HIGH RISK groups, the ranges of which end and begin in a value of 20%, how can one prevent superimposition
between groups (Pages 162-163).
c) Could the methodology of Risk Stratification be used for Prognosis Quantification presented on Table 3 for all patients with
blood hypertension, or this could only be applied to the patients between consecutive age ranges in the Framingham study, according
to what has been expressed in the final part of the first paragraph under the title "Stratification of patients with hypertension by
absolute level of cardiovascular risk"?
Cordially, Dr. Jorge P. Did

Top

#94 De:  Jorge Did Nunez<jdid@infomed.sld.cu>
Enviado: Miercoles, 15 Mar 2000 22:42:31
Asunto: Prevencion mediante evaluacion de riesgo absoluto/Prevention trough evaluatiov
Sponsored by: Deutsche Bank
Estimados colegas.
Estoy trasmitiendole una informacion que espero pueda ser de utilidad para todos.
....En la misma semana que el gobierno ha dado a conocer la Estructura del Servicio Nacional (National Service Framework)
para abordar las cardiopatias coronarias, el British Medical Journal, BMJ, publica una serie de articulos sobre la evaluacion de los
riesgos del paciente de desarrollar cardiopatias coronarias. En un editorial, Rod Jackson, profesor de epidemiologia en el Departamento
de Salud Comunitaria de la Universidad de Auckland, apoya las directivas clinicas britanicas que establecen que se debe dar prioridad para el tratamiento a los pacientes con riesgo absoluto elevado de padecer una cardiopatia coronaria, en lugar de centrarse en los
factores de riesgo individuales......
Los detalles se pueden encontrar en http://www.bmj.com/cgi/content/full/320/7236/659
(Guidelines on preventing cardiovascular disease in clinical practice)
Un cordial saludo a todos.

Dear colleagues:
I am sending this information to you, hoping that it may turn out useful for everyone.
...In the same week that the government has announced the National Service  Framework to approach coronary heart diseases, the
British Medical Journal, BMJ, published a series of articles about evaluation of risks of the patient for developing coronary heart
disease. In his editorial, Rod Jackson, professor of epidemiology at the Department of Communal Health from the University of Auckland,
supports British clinical guidelines that establish that priority must be given to the treatment for patients with high absolute
risk of suffering coronary heart disease, instead of centering in individual risk factors...
Details are available at: http://www.bmj.com/cgi/content/full/320/7236/659
(Guidelines on preventing cardiovascular disease in clinical practice)
Kind regards for everyone, Dr. Jorge Did

Top



© CETIFAC
Bioengineering
UNER

Update
Mar/22/2000